Samtidig administration af fosaprepitant og ergotalkaloidderivater, der er CYP3A4- substrater, kan medføre forhøjede plasmakoncentrationer af disse lægemidler.
Co-administration of fosaprepitant with ergot alkaloid derivatives, which are CYP3A4 substrates, may result in elevated plasma concentrations of these medicinal products.